A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies

The presence of residual cardiovascular disease (CVD) risk is a current dilemma in clinical practice; indeed, despite optimal management and treatment, a considerable proportion of patients still undergo major CV events. Novel lipoprotein biomarkers are suggested as possible targets for improving th...

Descripción completa

Detalles Bibliográficos
Autores principales: Vekic, Jelena, Zeljkovic, Aleksandra, Al Rasadi, Khalid, Cesur, Mustafa, Silva-Nunes, José, Stoian, Anca Pantea, Rizzo, Manfredi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879153/
https://www.ncbi.nlm.nih.gov/pubmed/35208183
http://dx.doi.org/10.3390/metabo12020108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8879153/
https://www.ncbi.nlm.nih.gov/pubmed/35208183
http://dx.doi.org/10.3390/metabo12020108

Ejemplares similares